ClinicalTrials.gg
RecruitingNCT06247657Updated Apr 3, 2024

A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours

A Phase 1 interventional study of BL0006 in Advanced Solid Tumor, sponsored by Shanghai Best-Link Bioscience, LLC. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Shanghai Best-Link Bioscience, LLC · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is the first in human study of BL0006, and the primary objective is to evaluate the safety and tolerability of BL0006 as a single agent in patients with advanced solid tumors.

Read the detailed description

This study consists of two parts: dose-escalation stage and dose-expansion stage.

The dose-escalation stage is designed to determine the maximum tolerated dose (MTD) and select recommended Phase 2 dose (RP2D) of BL0006 monotherapy. The dose-expansion stage will be conducted with selected doses to further evaluate the preliminary anti-tumor activity, safety and tolerability.

A total of approximately 19\~66 patients will be enrolled in the study.

Approximately 13-30 patients will be enrolled into dose-escalation of BL0006 . A total of 6\~36 patients each with advanced solid tumor will be evaluated in dose-expansion of BL0006.

Patients will continue to receive BL0006 as long as they are benefiting from treatment in the investigator's opinion and do not meet any other discontinuation criteria.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Shanghai Best-Link Bioscience, LLC is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and sign form.
  2. Aged ≥ 18 years, male and female.
  3. The dose-escalation stage: patients with or cytologically confirmed, unresectable or advanced solid tumors that have failed despite standard therapy, for whom no standard therapy exists, or who have refused standard therapy.
  4. The dose-expansion stage: patients with histologically or cytologically confirmed, unresectable or metastatic hepatocellular carcinoma (HCC) who are not suitable for surgery and local treatment, and who have failed despite standard therapy, or who have refused standard therapy. And other potential tumors (selection based on the results of BL0006-101 Study dose-escalation stage) that have failed despite standard therapy, for whom no standard therapy exists, or who have refused standard therapy.
  5. Patients with at least one per (v1.1) (applicable to the dose-expansion stage only).
  6. (ECOG) performance status score 0 or 1 at screening.
  7. period ≥ 12 weeks.
  8. A male patient must agree to use adequate from screening through at least 6 months after the last dose of product BL0006.
  9. Women of must have a negative pregnancy test prior to the dosing administration, and agree to use adequate contraception from screening through at least 6 months after the last dose of investigational product BL0006. A female participant of non-childbearing potential will have had at least 12 continuous months of natural (spontaneous) amenorrhoea, follicle stimulating hormone (FSH) level > 40 mIU/mL at screening, and an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms); or have had surgical bilateral oophorectomy, hysterectomy or bilateral tubal ligation beyond 6 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  1. Patients with symptomatic central nervous system (CNS) or carcinomatous meningitis.
  2. Patients who have a history of another primary (with the exception of subjects with cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix). A patient who has had no evidence of disease from another primary cancer for 5 or more years is allowed to participate in the study.
  3. Patients whose pericardial effusion, pleural effusion or ascites remain uncontrollable after intervention.
  4. Patients with a history of transplantation of organs, bone marrow or stem cell. Patients with a history of hepatic encephalopathy.
  5. Patients with Gilbert's syndrome disease.
  6. Patients with homozygous for UGT1A1*28 or UGT1A1*6.
  7. Patients who have impaired cardiac function or cardiac diseases, including any of the following:

    class III-IV for cardiac insufficiency or \< 50%.

    Patients with poorly controlled arrhythmia: > 480 ms calculated by Fridericia's formula, or congenital syndrome of prolonged QT interval.

    Any of the following within 6 months prior to the screening: myocardial infarction, severe or unstable angina, congestive heart failure, cerebrovascular accident (including ), symptomatic pulmonary embolism or other clinically significant thromboembolic disease, or coronary artery bypass graft.

    Clinically significant resting bradycardia. Patients with other clinically significant cardiovascular disease who were assessed as unsuitable for this study by the investigator.

  8. Patients with active chronic inflammatory bowel disease at screening (such as Ulcerative Colitis, Crohn's disease), ≥ grade 2 anorexia, nausea, vomiting or signs of intestinal obstruction. Or patients with a history of intestinal obstruction, gastrointestinal perforation, or clinically significant gastrointestinal bleeding within the 6 months prior to screening.
  9. Known history of clinically significant active (COPD), or other moderate-to-severe chronic respiratory illness present within 6 months.
  10. Patients who have a known diagnosis of (HIV) infection.
  11. Patients with active or chronic at screening ("active hepatitis" defined as HCV RNA level ≥ 200 IU/mL for hepatitis C or HBV DNA level ≥ 2000 IU/mL for hepatitis B at screening). In addition, eligible hepatitis B or hepatitis C patients must agree to antiviral treatment according to the treatment guidelines.
  12. Active infections requiring antibiotic intravenous therapy within 4 weeks prior to screening.
  13. Patients with any other medical conditions that, in the opinion of the Investigator, could affect the patient's participation in the study such as:

    Disease management may be jeopardized by treatment with this study treatment. Uncontrolled diabetes mellitus, ≥ 8%. Moderate or severe hepatic impairment, i.e., class B or C.

  14. Those who received blood transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor therapy within 2 weeks prior to screening.
  15. Patients who have not sufficient baseline organ function and whose laboratory data meet the following criteria at enrollment:

    (ANC) \< 1.5×109/L. Serum albumin \< 30 g/L. Total > 1.5×. (AST) or alanine aminotransferase (ALT) > 3×ULN without liver metastases or primary liver cancer. AST or ALT > 5×ULN if the patient has documented primary liver cancer or liver metastases.

    \< 90 g/L. \< 100×109 /L. \< 50 mL/min.

  16. Those who are known to be allergic to the active ingredient or of the product BL0006, or who have a predisposition to allergy.
  17. Patients with a history of an anaphylactic reaction to irinotecan, irinotecan liposome, sacituzumab govitecan-hziy or other topoisomerase I inhibitors, or ≥ Grade 3 hematology or gastrointestinal toxicity prior to irinotecan, irinotecan liposome, sacituzumab govitecan-hziy or other topoisomerase I inhibitors.
  18. Use of UGT1A1 inhibitors or inducers within 5 half-lives at the time of investigational product BL0006 administration, or planned use of UGT1A1 inhibitors or inducers within 2 weeks prior to administration of BL0006 (whichever is shorter), or are expected to continue such therapy during the study.
  19. Anti-tumor therapy within 5 half-lives at the time of investigational product BL0006 administration, or anti-tumor therapy within 4 weeks prior to administration of BL0006 (whichever is shorter), therapy including chemotherapy, biologic therapy, immunotherapy, radiotherapy (palliative radiotherapy for local pain control is excluded and the radiotherapy area do not include the proposed target lesion) and so on, or all relevant toxic reactions (except alopecia) have not been recovered.
  20. Patients who are taking anticoagulant therapy (prophylactic use of low-dose aspirin or low molecular weight heparin is allowed).
  21. Those who are expected to require systemic within 4 weeks prior to administration of BL0006 (low doses of corticosteroids are excluded, such as ≤ 10 mg prednisone daily or equivalent).
  22. Those who have received live or attenuated vaccines (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, BCG, typhoid vaccine, etc.) within 4 weeks before screening, or any covid-19 vaccine within 2 weeks before screening.
  23. Those who underwent major surgery within 4 weeks before screening, or plan to undergo major surgery during the study.
  24. Those who are participating in other clinical studies, or have participated in any other interventional clinical studies within 4 weeks before screening.
  25. Pregnant or lactating women.
  26. Patients who are judged disqualified to join clinical studies by investigator due to any causes.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    BL0006

    Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.

    Drug: BL0006

Interventions

  • DrugBL0006

    Patients will be administered BL0006 via intravenous infusion at the corresponding dose level on days 1 and 8 of a 21-days treatment cycle.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose(MTD)

    Based on the incidence of Dose-Limiting Toxicity (DLT) of BL0006 in patients with advanced solid tumors, MTD is determined.

    Time frame: Throughout the study for approximately 2 years

  2. Recommended Phase II Dose(RP2D)

    RP2D will be evaluated according to all the available safety, PK and efficacy data.

    Time frame: Throughout the study for approximately 2 years

Secondary outcomes

  1. Area under the plasma concentration-time curve (AUC)

    Area under the plasma concentration time curve

    Time frame: Cycle 1 day 1 to Cycle 2 day 2(each cycle is 21 days)

  2. Half life (t1/2)

    The elimination half-life time

    Time frame: Cycle 1 day 1 to Cycle 2 day 2(each cycle is 21 days)

  3. Disease Control Rate(DCR)

    DCR is defined as the proportion of subjects who achieve a Complete Response (CR) 、Partial Response (PR) or Stable Disease (SD) as assessed by RECIST v1.1

    Time frame: Throughout the study for approximately 2 years

  4. Objective response rate(ORR)

    ORR is defined as the proportion of patients with the best responses of Complete Response (CR) and Partial Response (PR) observed after study treatment.

    Time frame: Throughout the study for approximately 2 years

  5. Progression-Free Survival (PFS)

    PFS was defined as the the time from the start date of study treatment to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: Throughout the study for approximately 2 years

  6. Duration of overall response (DOR)

    DOR is defined as the time from the first documented CR or PR per RECIST v1.1 to disease recurrence or disease progression (PD) whichever occurs first.

    Time frame: Throughout the study for approximately 2 years

  7. One-year Overall Survival rate (OS 12)

    OS 12 is defined as the proportion of patients alive at one year after the start date of study treatment.

    Time frame: Throughout the study for approximately 2 years

07

Study locations

1 of 2 sites recruiting
  • The First Hospital of Jilin University
    Changchun, Jilin 130000, China
    Not yet recruiting
    • Yanan Wang · Contact
    • Yanan Wang · Principal investigator
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 200032, China
    Recruiting
    • Jia Fan · Contact
    • Jia Fan · Principal investigator
    • Tianshu Liu · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Oct 2024, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Feb 8, 2024
StartActual
Jan 3, 2024
Primary completionEst.
Oct 2024
CompletionEst.
May 2025
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06247657
Lead sponsor
Shanghai Best-Link Bioscience, LLC
Responsible party
Sponsor
First posted
Feb 8, 2024
Start date
Jan 3, 2024
Primary completion
Oct 2024 (estimated)
Completion
May 2025 (estimated)
Last update
Apr 3, 2024

Study contacts

Weixing Mao
Contact
maoweixing@bestlinkbio.com
+86-021-58383963

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion